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Abstract
Background: Although poor complementary feeding is associated with poor child growth, nutrition interventions
only have modest impact on child growth, due to high burden of infections. We aimed to assess the association of
malaria with linear growth, hemoglobin, iron status, and development in children aged 6–18 months in a setting of
high malaria and undernutrition prevalence.
Methods: Prospective cohort study, conducted in Mangochi district, Malawi. We enrolled six-months-old infants
and collected weekly data for ‘presumed’ malaria, diarrhea, and acute respiratory infections (ARI) until age 18months.
Change in length-for-age z-scores (LAZ), stunting, hemoglobin, iron status, and development were assessed at age
18months. We used ordinary least squares regression for continuous outcomes and modified Poisson regression for
categorical outcomes.
Results: Of the 2723 children enrolled, 2016 (74.0%) had complete measurements. The mean (standard deviation)
incidences of ‘presumed’ malaria, diarrhea, and ARI, respectively were: 1.4 (2.0), 4.6 (10.1), and 8.3 (5.0) episodes/child year.
Prevalence of stunting increased from 27.4 to 41.5% from 6 to 18months. ‘Presumed’ malaria incidence was associated
with higher risk of stunting (risk ratio [RR] = 1.04, 95% confidence interval [CI] = 1.01 to 1.07, p = 0.023), anemia (RR = 1.02,
95%CI = 1.00 to 1.04, p = 0.014) and better socio-emotional scores (B =− 0.21, 95%CI = − 0.39 to − 0.03, p = 0.041), but not
with change in LAZ, haemoglobin, iron status or other developmental outcomes. Diarrhea incidence was associated with
change in LAZ (B = − 0.02; 95% CI = − 0.03 to − 0.01; p = 0.009), stunting (RR = 1.02; 95% CI = 1.01 to 1.03; p = 0.005), and
slower motor development. ARI incidence was not associated with any outcome except for poorer socio-emotional
scores.
Conclusion: In this population of young children living in a malaria-endemic setting, with active surveillance and
treatment, ‘presumed’ malaria is not associated with change in LAZ, hemoglobin, or iron status, but could be
associated with stunting and anemia. Diarrhea was more consistently associated with growth than was malaria or
ARI. The findings may be different in contexts where active malaria surveillance and treatment is not provided.
Trial registration: NCT00945698 (July 24, 2009) and NCT01239693 (November 11, 2010).
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Introduction
Although poor complementary feeding is associated with
poor child growth, many interventions designed to improve
complementary foods only have modest impact on growth
[1], possibly due to a high burden of infections in children
[2, 3]. Studies in which morbidity treatment was integrated
with a complementary feeding intervention demonstrated
improved linear growth [4] and developmental outcomes
in children [5, 6], suggesting the importance of reducing
the burden of infections along with improved diet to
promote child growth and development.
Longitudinal studies have reported a significant inverse
association of diarrhea with growth [7–9]. However, studies
on the association of malaria with growth and development
have either reported inconsistent results or had cross-sec-
tional designs, which makes it difficult to assess causality or
directionality of association [10–13]. This has prevented
the inclusion of malaria as a determinant of stunting in the
Lives Saved Tool (LiST) model [14].
The International Lipid-based Nutrient Supplements
(iLiNS) Project DOSE and DYAD-M studies were ran-
domized controlled trials conducted in Malawi to study
the impact of lipid-based nutrient supplements (LNS) on
growth of children [15, 16]. The aim of this analysis was
to assess the association of malaria with linear growth,
hemoglobin, iron status, and child development. Our
hypothesis was that linear growth, hemoglobin, iron status,
and developmental outcomes at age 18 mo would be
poorer in children with higher incidence of malaria
from age 6 to 18 mo. We also analyzed the association
of diarrhea and acute respiratory infections (ARI) with
linear growth, hemoglobin, iron status, and developmental
outcomes.
Methods
Study setting
The iLiNS-DOSE and iLiNS-DYAD-M studies were
conducted in one public district hospital (Mangochi),
one mission hospital (St Martins), and two rural public
health centers (Lungwena and Namwera) in Mangochi
District, Southern Malawi. The total catchment population
of 180,000 largely subsisted on farming and fishing. In
Malawian children aged < 5 years, the prevalence of
reported fever (a proxy for malaria), diarrhea and ARI
was 29, 22 and 5%, respectively, with seasonal fluctuations
[17]. Malaria is endemic in Malawi and the study area has
high malaria transmission with high temperature and fre-
quent rainfall from October through April [18].
Study design and data collection
In the iLiNS-DOSE study, 6-mo old children were
randomly allocated to one of five intervention groups
provided with different doses or formulations of LNS
or to a control group that did not receive LNS during
the 12-mo study period, between November 2009 and
May 2012. In the iLiNS-DYAD-M study, pregnant women
< 20 weeks’ gestation were randomly allocated to one of
three groups to receive iron and folic acid (IFA), multiple
micronutrients (MMN) or a small-quantity (20 g) of LNS
daily. After delivery, women in the IFA group received pla-
cebo tablets, while MMN and LNS supplementation was
continued up to 6 mo postpartum. Children of mothers in
the LNS group also received LNS 10 g twice daily from
age 6 to 18 mo. This study was conducted from February
2011 to April 2015. Details of study design, randomization
and enrolment for the two studies were explained in the
main outcome papers [15, 16].
In both studies, research assistants visited the children’s
homes every week from age 6 to 18 mo to interview the
guardians about the child’s health in the previous 7 days
using a structured questionnaire. The information was
complemented by a picture calendar filled out by the
guardians daily to aid memory of their children’s mor-
bidity status. The use of maternal interviews as a means
of collecting data on child morbidity has been validated
in previous studies [19, 20]. The research assistants
referred all cases of ‘presumed’ malaria (presence of
fever) to the nearby health facility for treatment with
lumefantrine/artemether, the nationally recommended
antimalarial drug. The children were followed throughout
the year, covering periods of both high and low malaria
transmission.
Anthropometric measurements were taken at age 6 mo
and 18 mo. Study anthropometrists measured the infant’s
length with a high-quality length board (Harpenden
Infantometer; Holtain Limited) and recorded it to the
nearest 1mm. They weighed unclothed infants with elec-
tronic infant weighing scale (SECA 735; Seca GmbH &
Co), recording to the nearest 10 g. The anthropometrists
were trained and their measurement reliability was veri-
fied at the start of the study and at 6-mo intervals there-
after with methods adapted from the procedures used in
the WHO Multicentre Growth Reference Study [21]. The
anthropometrists calibrated all equipment with standard
weights and length rods daily.
We assessed iron status at age 6 mo and 18 mo by
measuring the zinc protoporphyrin (ZPP) concentration
in unwashed venous blood sample using a hematofluorom-
eter (206D, AVIV Biomedical Inc., Lakewood, NJ, USA).
About 5–7ml of blood was collected by venepuncture
using a 23-gauge needle into 7.5ml evacuated, trace
element-free polyethylene tubes containing lithium heparin
(Sarstedt AG & Co, Nümbrecht, Germany). The samples
were kept covered in aluminium and away from light, in a
refrigerator or on ice, and processed within 2 h of collec-
tion. We measured blood hemoglobin (Hb) concentration
at age 6 mo and 18 mo from a drop of blood taken from a
finger prick and collected in a microcuvette. Hb analysis
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was conducted on-site using a Hemo-Cue instrument
(Hemocue 201+, HemoCue® AB, Ängelholm, Sweden).
We assessed fine and gross motor development at age
18 mo using the Kilifi Developmental Inventory (KDI)
developed in Kenya [22]. Language development was
assessed using a 100-word vocabulary checklist by maternal
interview based on the MacArthur-Bates Communicative
Development Inventory [23] adapted for the local languages,
and 18-mo socio-emotional development was assessed using
the Profile of Social and Emotional Development (PSED),
also developed in Kenya. The child’s mood during the KDI
assessment was rated as positive (smiling/laughing) or not
positive (crying/inconsolable, changeable/mood swings, or
no visible emotions). The child’s interaction with the asses-
sor during the KDI was rated as positive (friendly) or not
positive (avoidant and withdrawn, clings to family member,
hesitant/when approached will accept reluctantly, diffi-
cult to engage in tasks, or inappropriate approaches to
the assessor). The child’s activity level during the KDI
was rated as positive (active and maintains interest) or
not positive (unarousable, sleepy and can hardly be awak-
ened, sleepy but easily awakened, does not spontaneously
engage in activity, and awake but loses interest). The KDI,
vocabulary, and PSED scores showed high inter-rater
agreement and moderate to high test-retest reliability in
this study setting [24, 25].
Definition of the predictors and the outcomes
We used a presumptive diagnosis of malaria derived from
episodes of fever during the previous week, reported by
the guardians. To ensure the diagnoses were mutually
exclusive, we created an algorithm whereby any fever with
a diarrhea episode (three or more loose stools in 24 h) was
categorized as diarrhea; any fever in the presence of any
respiratory symptoms (cough, rapid or difficult breathing
and nasal discharge) was categorized as ARI. ‘Presumed’
malaria was defined as any fever episode in the absence of
diarrhea and respiratory symptoms.
An episode of ‘presumed’ malaria, ARI or diarrhea
was defined as the period starting from the day the child
had the symptoms when preceded by at least 2 days of
no symptoms or no data. The episode ended on the last
day the child had the symptoms which was then
followed by at least 2 symptom-free days. Incidence of
‘presumed’ malaria, ARI or diarrhea for each child from
age 6 to 18 mo was calculated as total episodes / total
follow up years at risk.
Longitudinal prevalences of common childhood symp-
toms (fever, diarrhea, and cough) from age 6 to 18 mo were
defined as the number of days with the symptom divided by
the total number of days of observation for each child [26].
We calculated age- and sex-standardized anthropometric
indices [length-for-age z score (LAZ), weight-for-age z
score (WAZ), and weight-for-length z score (WLZ)] based
on the WHO Child Growth Standards [21] and considered
values below – 2.0 indicative of underweight, stunting and
wasting, respectively. Change in LAZ for each child was
calculated as the difference between LAZ at age 18 mo
and LAZ at age 6 mo.
Iron deficiency at age 6 mo and 18 mo was defined as
whole blood ZPP > 70 μmol/mole heme [27]. Anemia at
age 6 mo was defined as blood Hb concentration < 105 g/L
[28] while anemia at age 18 mo was defined as blood Hb
concentration < 110 g/L [29].
From the child development data at age 18 mo, fine
motor scores were calculated as the sum of 34 KDI fine
motor items, each scored 0 or 1, gross motor scores
were calculated as the sum of 35 KDI gross motor items,
each scored 0 or 1 [22] and vocabulary score was the
maternal-reported child expressive vocabulary out of the
100-word checklist. For these outcomes, moderate to
severe delay was defined as the bottom 25% of the sample.
The socio-emotional score was calculated as the sum of
19 PSED items. Moderate to severe delay was defined as
the top 25% of our sample (a higher score indicates less
advanced socio-emotional development).
Statistical analysis
We included in the analysis children who had outcomes
measured at age 18 mo. For all continuous outcomes,
we used ordinary least squares regression to assess the
association between malaria incidence and each outcome;
and for all binary outcomes, we used modified Poisson
regression (with a robust variance estimator) [30].
We first assessed whether the relationship between the
predictor and each outcome differed between the two
studies. However, the interaction term was not statistically
significant indicating that this relationship was not differ-
ent between the two studies therefore we pooled data
from the two cohorts. We then constructed multivariate
models to determine which variables independently pre-
dicted the outcomes. We included all theoretically rele-
vant variables, regardless of whether they were statistically
significant or not after the bivariate analysis. The following
variables collected at age 6 mo were included in the
models: child sex, LAZ, WLZ, Hb, iron status, maternal
education and household food insecurity access (HFIA)
score generated by summing the value of responses to
nine questions regarding food insecurity [31]. We also in-
cluded in the models, from age 6 to 18 mo, the incidence
of diarrhea and ARI, and whether the child received an
intervention (LNS) or not. For the risk of stunting at age
18 mo, we included in the model stunting at age 6 mo (in
place of LAZ). In addition, all developmental outcomes
were adjusted for the child’s mood, activity level, age and
interaction with the assessor.
We assessed collinearity among the variables (e.g. LAZ
vs WLZ at age 6 mo). If the variables were highly collinear
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(> 0.5), we dropped the one that was less strongly associ-
ated with the outcomes. We accounted for intracluster
correlation due to twins using generalised estimating
equations [32].
We also performed exploratory analyses by using fre-
quency of malaria episodes (from age 6 to 18 mo) as a cat-
egorical variable (no episode, one episode, and > 1 episodes
groups). In addition, we conducted stratified analyses by
stunting at age 6 mo. Although we performed bivariate
analyses for each individual variable, we will only report
the results from multivariate analysis.
We used Stata version 14 (StataCorp, Texas, USA) for
all the analyses.
Results
Baseline characteristics and descriptive statistics
Of the 2723 children enrolled in the two study cohorts,
2016 (74.0%) had length measured both at age 6 mo and
18 mo (1417 children from the iLiNS DOSE study and
599 children from the iLiNS DYAD-M study). These were
included in the final analysis (Fig. 1). The characteristics
of these children at age 6 mo are summarized in Table 1.
The 2016 children included in the final analysis con-
tributed 1647.9 child years of follow up, i.e. the mean
(standard deviation) [SD] duration of follow up was 298
(61) days / child. A total of 24,024 morbidity episodes
were reported during the home visits. Of these, 9.7%
(2324/24024) were episodes of ‘presumed’ malaria. The
rest of the morbidity episodes were due to: acute respiratory
infections (ARI), 55.6% (13,360/24024); diarrhea, 33.6%
(8083/24024); and minor conditions, 1.1% (257/24024).
Overall, the mean (SD) incidence of all illnesses com-
bined was 14.8 (6.8) episodes per child year. The mean
(SD) incidence of ‘presumed’ malaria was 1.4 (2.0) episodes
per child year. The mean (SD) incidence of ARI was 8.3
(5.0) episodes per child year and the mean (SD) incidence
of diarrhea was 4.6 (10.1) episodes per child year. The
longitudinal prevalences of common childhood symptoms
(fever, diarrhea, and cough) from age 6 to 18 mo were:
7.5%; 3.4%; and 11.7%, respectively.
During the 12-mo follow up period, 39.0% (787/2016)
of the children did not report any episode of ‘presumed’
malaria, 30.3% (611/2016) reported one episode and 30.7%
(618/2016) reported > 1 malaria episodes. The children
who reported > 1 malaria episodes were responsible for
869 pregnant women enrolled in complete 
follow up, randomized to receive either LNS, 
MMN or IFA
791 live births, including 5 sets of twins
599 children with length data at both 
time points 
656 children completed follow up
- Length assessment
- Zinc protoporphyrin (iron status)
- Haemoglobin assessment
- Developmental assessment
42 deaths
93 drop outs
57 missing length data 
either at age 6 or 18 mo
iLiNS DYAD Study iLiNS DOSE Study
2136 age-eligible infants invited to the trial 
office for a detailed eligibility assessment
118 missing length data 
either at age 6 or 18 mo
1417 children with length data at both 
time points 
2016 children pooled 
from the two studies
73 drop outs
20 miscarriages or 
stillbirths
110 under age
53 over age
7 out of catchment area
20 refused
14 reasons not known
1932 infants enrolled and randomized into 6 groups
- Length assessment
- Weight assessment
- Zinc protoporphyrin (iron status)
- Haemoglobin assessment
791 infants came for clinic visit at age 6 mo
- Length assessment
- Weight assessment
- Zinc protoporphyrin (iron status)
- Haemoglobin assessment
78 deaths
319 drop outsMorbidity data collection
1535 children completed follow up
- Length assessment
- Zinc protoporphyrin (iron status)
- Haemoglobin assessment
- Developmental assessment
Included in the final analysis
Age 18 mo
Age 6 mo
Fig. 1 Flow chart of the children enrolled and included in the final analysis. The figure shows the number of children enrolled, children lost to
follow up, and children who were eventually included in the study from the iLiNS DOSE and iLiNS DYAD-M cohorts
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73.7% (1713/2324) of all ‘presumed’ malaria episodes
reported in the two studies.
At age 18 mo, the mean (SD) length-for-age z-scores
(LAZ), weight-for-age z-scores (WAZ) and weight-for-
length (WLZ) scores were − 1.8 (1.1), − 1.0 (1.1) and − 0.2
(1.1) respectively. The proportions of children who were
stunted, underweight and wasted were 41.5, 16.6 and
5.0%, respectively. The median (25th, 75th centile) zinc
protoporphyrin (ZPP) concentration was 74 (51, 114)
μmole/mole heme and the proportion with iron deficiency
was 54.1%. The mean (SD) hemogobin (Hb) concentration
was 108.5 (15.1) g/L and the proportion with anemia was
50.5%. The mean (SD) scores for fine motor, gross motor,
language and Profile of Social and Emotional Develop-
ment (PSED) were 20.9 (2.2), 17.3 (2.6), 26.2 (5.0) and 16.2
(5.4) respectively.
Association of malaria with linear growth
The mean (SD) change in LAZ from age 6 to 18 mo was −
0.44 (0.77). In multivariate analysis, there was no association
between the incidence of ‘presumed’ malaria and change in
LAZ from age 6 to 18 mo, adjusted for LAZ at age 6 mo
(B = − 0.02, 95% CI = − 0.04 to 0.01, p = 0.069) (Table 2).
The proportion of children who were stunted increased
from 27.4% at age 6 mo to 41.5% at age 18 mo. In multi-
variate analysis, the incidence of ‘presumed’ malaria was
associated with higher risk of stunting at age 18 mo,
adjusted for stunting at age 6 mo (RR= 1.04, 95% CI = 1.01
to 1.07, p= 0.023) (Table 2). When categorized by frequency
of malaria episodes and adjusted for stunting at age 6 mo,
children with > 1 malaria episodes from age 6 to 18 mo had
higher risk of stunting at age 18 mo compared to children
with zero malaria episodes (RR = 1.39, 95% CI = 1.13 to 1.70,
p= 0.002).
Association of malaria with hemoglobin, anemia and iron
status
The incidence of ‘presumed’ malaria from age 6 to 18 mo
was associated with higher risk of anemia at age 18 mo,
adjusted for hemoglobin at age 6 mo (RR = − 0.12; 95%
CI = − 0.20 to − 0.04; p = 0.002) but not with hemoglobin
or iron deficiency at age 18 mo (Table 3).
Association of malaria with child development
The association of incidence of ‘presumed’ malaria from
age 6 to 18 mo with child development was significant for
PSED scores (B = − 0.21; 95% CI = 0.39 to − 0.03; p = 0.041),
but not for the other domains of child development,
adjusted for the covariates listed in the footnotes to
Tables 4 and 5.
Association of diarrhea and ARI with linear growth,
hemoglobin, iron status, and developmental outcomes
In multivariate analysis, incidence of diarrhea from age 6
to 18 mo was associated with change in LAZ from age 6
to 18 mo (B = − 0.02; 95% CI = − 0.03 to − 0.01; p = 0.009),
higher risk of stunting at age 18 mo (RR = 1.02; 95% CI =
1.01 to 1.03; p = 0.005) (Table 2), lower gross motor scores
Table 1 Participant characteristics at age 6 mo
Variable DOSEa DYAD-Ma Pooled dataa
Number of childrenb 1417 599 2016
Proportion of boys 50.5% 47.6% 49.6%
Mean (SD) weight, kg 7.0 (1.0) 7.3 (1.0) 7.1 (1.0)
Mean (SD) length, cm 63.4 (2.4) 64.2 (2.6) 63.6 (2.5)
Mean (SD) weight-for-age z-score −0.7 (1.1) − 0.5 (1.2) − 0.7 (1.2)
Mean (SD) length-for-age z-score −1.4 (1.0) − 1.2 (1.1) − 1.4 (1.1)
Mean (SD) weight-for-length z-score 0.3 (1.1) 0.4 (1.1) 0.3 (1.1)
Mean (SD) hemoglobin, g/L 103.6 (16.1) 103.7 (15.3) 103.6 (15.9)
Proportion with LAZ < −2 scores 29.1% 23.4% 27.4%
Proportion with Hb < 105 g/L 50.6% 54.4% 51.7%
Proportion with ZPP > 70 μmole/mole hemec 68.7% 69.8% 69.0%
Proportion with malariad 16.7% 9.7% 14.5%
Mean (SD) maternal education, completed years 4.7 (3.6) 3.8 (3.5) 4.4 (3.6)
Mean (SD) maternal age, years 26.1 (6.2) 25.1 (6.0) 25.8 (6.1)
Mean (SD) Household Food Insecurity Access Score 6.5 (6.0) 5.0 (4.3) 6.0 (5.6)
aValues are n, mean (SD) or proportions
bChildren who had length data at age 6 mo and 18 mo
cMeasured from unwashed venous blood
dMeasured by malaria antigen Rapid Diagnosis Test (mRDT)
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at age 18 mo (B = − 0.02; 95% CI = − 0.03 to − 0.01; p <
0.001), and higher risk of gross motor delay (RR = 1.01;
95% CI = 1.00 to 1.02; p < 0.001) and fine motor delay
(RR = 1.01; 95% CI = 1.00 to 1.02; p = 0.011) at age 18 mo
(Tables 4 and 5).
The incidence of ARI from age 6 to 18 mo was not
significantly associated with growth or other outcomes
except for PSED scores (B = 0.08; 95% CI = 0.03 to 0.14;
p = 0.004), and PSED delay (RR = 1.02; 95% CI = 1.00 to
1.04; p = 0.025) (Tables 4 and 5).
Table 2 Association of infectious disease morbidity from age 6 to 18 mo with change in LAZ and stunting at age 18 mo
Variables Mean change in LAZ from age 6 to 18 mo Stunting at age 18 mo
(N = 2016) (N = 2016)
Regression coefficienta (95%
CI)
P-value Risk ratiob (95% CI) P-value
Incidencec of ‘presumed’ malaria − 0.02 (− 0.04 to 0.01) 0.069 1.04 (1.01 to 1.07) 0.023
> 1 malaria episodes (vs no malaria
episode)
− 0.04 (− 0.12 to 0.04) 0.363 1.23 (1.02 to 1.49) 0.034
Incidencec of diarrhea − 0.02 (− 0.03 to − 0.01) 0.009 1.02 (1.01 to 1.03) 0.005
Incidencec of ARI 0.01 (− 0.01 to 0.01) 0.614 0.99 (0.98 to 1.00) 0.097
Other predictorsd:
Female sex (vs. male) 0.09 (0.02 to 0.16) 0.012 0.92 (0.78 to 1.09) 0.352
LAZ at age 6 mo −0.27 (− 0.30 to − 0.24) < 0.001 Not included in the
model
Not included in the
model
WLZ at age 6 mo 0.14 (0.11 to 0.17) < 0.001 0.76 (0.69 to 0.82) < 0.001
Hemoglobin (g/L) at age 6 mo 0.01 (−0.01 to 0.01) 0.943 0.98 (0.97 to 0.99) 0.009
Stunting at age 6 mo Not included in the model Not included in the
model
3.02 (2.72 to 3.35) < 0.001
HFIA score −0.01 (−0.01 to 0.01) 0.155 1.02 (1.00 to 1.03) 0.025
ARI acute respiratory infection, CI confidence interval, HFIA household food insecurity access, LAZ length for age z-score, WLZ weight for length z-score
aObtained by ordinary least squares regression
bObtained by modified poisson regression (with a robust variance estimator)
cTotal episodes/child years at risk
dOnly predictors that showed statistical significance in any of the multivariate models are presented. Other variables entered in the regression, but not significant
in any model, were: iron status at age 6 mo; maternal education; and whether the child received an intervention (LNS) during the study period
Table 3 Association of infectious disease morbidity from age 6 to 18 mo with hemoglobin, anemia and iron deficiency at age 18 mo
Variables Mean hemoglobin (g/L) at age 18 mo Anemiaa at age 18 mo Iron deficiencyb at age 18 mo
(N = 1157) (N = 1157) (N = 1707)
Regression coefficientc P-value Risk ratiod P-value Risk ratiod P-value
(95% CI) (95% CI) (95% CI)
Incidencee of ‘presumed’ malaria −0.43 (− 1.21 to 0.34) 0.273 1.02 (1.00 to 1.04) 0.014 1.01 (0.99 to 1.02) 0.223
> 1 malaria episodes (vs no malaria episode) −1.80 (−3.74 to 0.14) 0.068 1.14 (1.02 to 1.27) 0.022 1.05 (0.95 to 1.17) 0.304
Incidencee of diarrhea 0.01 (−0.06 to 0.08) 0.767 1.00 (0.99 to 1.01) 0.370 1.00 (0.99 to 1.01) 0.776
Incidencee of ARI 0.09 (− 0.11 to 0.31) 0.392 1.00 (0.99 to 1.01) 0.671 1.00 (0.99 to 1.01) 0.772
Other predictorsf:
WLZ at age 6 mo 1.10 (0.21 to 1.99) 0.015 0.98 (0.94 to 1.02) 0.248 0.99 (0.96 to 1.03) 0.811
Hemoglobin (g/L) at age 6 mo 0.21 (0.15 to 0.28) < 0.001 0.98 (0.97 to 0.99) < 0.001 1.05 (0.96 to 1.14) 0.283
ZPP > 70 μmole/mole heme at age 6 mo −0.64 (− 2.42 to 1.14) 0.483 1.03 (0.92 to 1.15) 0.632 1.95 (1.71 to 2.23) < 0.001
ARI acute respiratory infection, CI confidence interval, WLZ weight for length z-score, ZPP zinc protoporphyrin
aDefined as blood hemoglobin concentration < 110 g/L [29]
bDefined as whole blood ZPP > 70 μmol/mole heme [27]
cObtained by ordinary least squares regression
dObtained by modified poisson regression (with a robust variance estimator)
eTotal episodes/child years at risk
fOnly predictors that showed statistical significance in any of the multivariate models are presented. Other variables entered in the regression, but not significant
in any model, were: length for age z-score at age 6 mo; child sex; maternal education; household food insecurity access score; and whether the child received an
intervention (lipid-based nutrient supplements) during the study period
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Discussion
We tested the hypothesis that the linear growth,
hemoglobin, iron status, and developmental outcomes at
age 18 mo would be poorer in children with higher inci-
dence of ‘presumed’ malaria. In a sample of 2016 Malawian
children aged 6–18 mo, we found that malaria was not
associated with change in LAZ, fine motor scores, gross
motor scores, language development, iron status or
hemoglobin concentration. Higher incidence of ‘presumed’
malaria was associated with higher risk of stunting and
anemia (i.e: one additional episode of ‘presumed’ malaria
per year was associated with 4 and 2% higher risk of
stunting and anemia, respectively). Higher incidence of
‘presumed’ malaria was also associated with lower
socio-emotional scores (i.e: one additional episode of
‘presumed’ malaria per year was associated with a reduc-
tion in PSED scores by 0.21), suggesting that children with
higher malaria incidence tended to have fewer socio-emo-
tional problems, possibly because malaria causes leth-
argy and inactivity which may manifest as fewer
behavioral problems.
Our study had several strengths: the weekly home
morbidity data collection for 1 year provided comprehen-
sive data covering periods of both high and low malaria
transmission; the longitudinal design made it possible to
correlate the malaria exposure with the outcomes and
interpret the directionality of association; and pooling of
data from two studies helped us draw conclusions from a
large sample. Although we did not calculate post-hoc
power for this analysis, with a large sample size of 2016
children and narrow confidence intervals obtained for
most of the morbidity outcomes, we believe the study was
powered to detect clinically meaningful associations.
Our results should be interpreted with caution because
we excluded children who did not have the outcomes
measured at age 18 mo (26% of the sample), resulting in
possible survival bias. However, this attrition rate is simi-
lar to that of other studies with a long follow up period
[9, 10]. Moreover, we expect that the children lost to follow
up may have had worse outcomes, which probably would
have increased the strength of association in our findings.
Another possible cause of bias is the presumptive diag-
nosis of malaria, which could lead to misclassification.
There is overlap in the symptoms of malaria, diarrhea and
ARI [33] which may affect the sensitivity and specificity of
presumptive malaria diagnosis depending on the intensity
of malaria transmission. For example, presumptive malaria
diagnosis usually has higher sensitivity and lower specifi-
city in areas of high malaria transmission compared to
areas of low transmission [34, 35]. With the global decline
in malaria incidence and availability of malaria Rapid
Diagnostic Tests (mRDTs), the WHO in 2010 recom-
mended antimalarial treatment be provided when there is
evidence of a positive malaria test result [36]. However, at
the time of conducting our study, mRDTs had not been
rolled out nationwide, hence presumptive malaria diagno-
sis was used not only in this study but also in national
prevalence surveys [18, 37], according to the practice of
Integrated Management of Childhood Illness (IMCI)
[38, 39]. Furthermore, in exploratory analysis using
hospital diagnosed malaria (confirmed by mRDT, albeit
with a lot of missing data), the direction of the associa-
tions was similar, suggesting that our findings are still
valid (data not shown).
Our research assistants referred the children suspected
of malaria to a clinic for treatment; the active surveillance
and early treatment may have helped improve the study
outcomes, which may have resulted in underestimation of
the associations.
It is also possible that the association of malaria with
stunting, anemia, and PSED scores was significant by
chance due to multiple testing [40]. However, we believe
the chance finding was less likely for the significant associa-
tions of diarrhoea and ARI with the outcomes because
these associations were relatively strong based on p-values.
The available evidence on the association of malaria
with growth and other outcomes is inconclusive. Some
studies have reported significant associations of malaria
with stunting, hemoglobin concentration, iron status and
child development [11, 12, 41–44]. Children living in set-
tings where infectious diseases are frequent and comple-
mentary food is of poor quality often fail to achieve catch
up growth after illness episodes [45], hence frequent
malaria could be associated with growth faltering. Earlier
evidence suggested that anorexia, vomiting, and a catabolic
state are responsible for the poor growth associated with
febrile illnesses in children [46]. However, other studies
have reported no association of malaria with growth out-
comes [47–50]. Similar to our study, most of these studies
provided active malaria diagnosis and treatment, which
may have attenuated the strength of the association.
In the studies cited above, different exposure and out-
come measures were used, which may also explain the
inconsistency in the findings. For example, we defined
linear growth as change in LAZ and stunting. Change in
LAZ indicates the growth rate between two time-points
and therefore provides more information about linear
growth faltering than stunting status assessed at one time-
point [51, 52]. Therefore, it is possible that there is no
association between malaria and linear growth (based on
change in LAZ), hemoglobin or iron status, or the associ-
ation is very weak. It is also possible that the association
between malaria and these outcomes is only seen in children
in the left end of the curve (i.e. LAZ < − 2 or hemoglobin <
110 g/L), hence the significant association of malaria with
stunting and anemia but not change in LAZ or hemoglobin
concentration. In contrast, diarrhea incidence was associated
with an entire leftward shift in LAZ and gross motor scores
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in this population. A leftward shift in mean LAZ for a popu-
lation is associated with increased risk of mortality [53].
The association of diarrhea with growth has been reported
in previous studies [7–9]. Frequent diarrhea episodes result
in persistent loss of nutrients necessary for growth through
malabsorption, changes in gut microbiota, continuous im-
mune system activation, increased metabolism and anorexia
resulting in growth suppression. In our study, the magnitude
of the significant associations of malaria and diarrhea with
the outcomes were small, consistent with other studies
[7, 42, 44, 54–56]. This could be partly attributable to
the active surveillance and treatment provided to all
children, or unmeasured confounding [44], or that perhaps
other conditions such as chronic inflammation and envir-
onmental enteric dysfunction may be more important
determinants of child growth in developing countries [57,
58]. Nevertheless, in a study combining nutrition interven-
tion with treatment of malaria and diarrhea there was
greater growth velocity, a 25% reduction in prevalence of
stunting and improved developmental outcomes at age
18 months [4], suggesting that interventions that com-
bine improved nutrition with control of infections may
have significant impact.
Conclusions
We conclude that in this population of children aged
6–18 mo living in a malaria-endemic setting, with active
surveillance and early treatment, ‘presumed’ malaria is
not associated with change in LAZ, hemoglobin or iron
status, but could be associated with stunting and anemia.
In this population, diarrhoea was more consistently associ-
ated with growth than was malaria or ARI. These findings
may be different in contexts where there is no active
case finding and treatment for malaria is not promptly
administered.
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